Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics to Provide Testing Services to Isis for Clinical Study

NEW YORK (GenomeWeb) – Interleukin Genetics today said that it will provide its genetic testing services to Isis Pharmaceuticals for a Phase II clinical study evaluating the novel therapeutic ISIS-APO(a)Rx in patients with high levels of lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease.

Interleukin's genetic test panels for inflammatory and metabolic diseases will be used to investigate genetic factors that may add value to the clinical trial, Interleukin CEO Kenneth Kornman said in a statement, adding that in a recent study, the company, using its assays, was able to identify patients with elevated Lp(a) levels who also overproduced interleukin-1.

Patients with elevated levels of Lp(a) are at an increased risk for atherosclerosis, coronary heart disease, aortic stenosis, heart attack, and stroke. Isis is developing ISIS-APO(a)Rx to inhibit the production of the apolipoprotein(a) component of Lp(a) and to treat patients with high levels of the lipoprotein who are at risk for life-threatening cardiovascular events.

According to Isis, the Phase II study will evaluate the safety and efficacy of ISIS-APO(a)Rx. The 12-week study will evaluate 100 mg, 200 mg, and 300 mg doses of the drug in about 60 patients with Lp(a) levels of at least 50 mg/dL. An average level of 30mg/dL is considered normal, Interleukin said, citing the National Institutes of Health. 

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.